Search results for "tips"

showing 10 items of 280 documents

Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis.

2013

This randomized open-label study compared the incidence of metabolic side effects of aripiprazole, ziprasidone and quetiapine in a population of medication-naive first-episode psychosis patients. A total of 202 subjects were enrolled. Body weight, body mass index, leptin, fasting lipids and fasting glycaemic parameters were measured at baseline and at 3 months follow-up. A hundred and sixty-six patients completed the follow-up and were included in the analyses. A high proportion of patients experienced a significant weight increase (>7% of their baseline weight): 23% ziprasidone (n=12), 32% with quetiapine (n=16) and 45% with aripiprazole (n=31). Patients treated with aripiprazole gained si…

AdultMalemedicine.medical_specialtyPsychosisDibenzothiazepinesPopulationAripiprazoleQuinolonesWeight GainGastroenterologyPiperazinesQuetiapine FumarateSex FactorsInternal medicinemedicineHumansZiprasidoneeducationPsychiatryBiological Psychiatryeducation.field_of_studybusiness.industryLeptinmedicine.diseaseProlactinPsychiatry and Mental healthThiazolesCholesterolPsychotic DisordersQuetiapineAripiprazoleFemalemedicine.symptombusinessWeight gainBody mass indexmedicine.drugAntipsychotic AgentsFollow-Up StudiesSchizophrenia research
researchProduct

Metabolic Syndrome and Cardiovascular Risk in People Treated with Long-Acting Injectable Antipsychotics

2017

BACKGROUND People with schizophrenia and other severe mental disorders have an increased mortality mainly attributed to natural causes, specifically cardiovascular disease and cancer. The metabolic syndrome and the Framingham Risk Score are epidemiologic tools related to long-term cardiovascular disease risk and they are increased in people with severe mental disorders. This increase has been attributed both to the disorder itself and to the use of antipsychotic drugs. OBJECTIVE To quantify the cardiovascular risk in a group of people treated with long-acting injectable antipsychotics. METHODS This is a cross-sectional study developed in an outpatient mental health clinic in which the preva…

AdultMalemedicine.medical_specialtyPsychosisHealth StatusEndocrinology Diabetes and Metabolismmedicine.medical_treatmentHealth BehaviorDiseasePharmacologyRisk AssessmentSeverity of Illness IndexInjectionsHabitsYoung Adult03 medical and health sciences0302 clinical medicineCost of IllnessRisk FactorsInternal medicinePrevalencemedicineHumansImmunology and AllergyAntipsychoticLife StyleAgedMetabolic SyndromeFramingham Risk Scorebusiness.industryMental DisordersMiddle Agedmedicine.diseaseMental healthObesity030227 psychiatryCross-Sectional StudiesCardiovascular DiseasesSpainSchizophreniaDelayed-Action PreparationsFemaleMetabolic syndromebusiness030217 neurology & neurosurgeryAntipsychotic AgentsEndocrine, Metabolic & Immune Disorders - Drug Targets
researchProduct

Outcome of suicidal patients with schizophrenia: results from a naturalistic study.

2010

Schennach-Wolff R, Jager M, Seemuller F, Obermeier M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkotter J, Heuser I, Maier W, Lemke MR, Ruther E, Klingberg S, Gastpar M, Moller H-J, Riedel M. Outcome of suicidal patients with schizophrenia: results from a naturalistic study. Objective:  Purpose was to assess suicidality before and at the time of admission in patients with schizophrenia and compare outcome differences. Method:  Biweekly PANSS (Positive and Negative Syndrome Scale), HAMD (Hamilton Depression Rating Scale) and UKU (Udvalg for Klinske Undersogelser Side Effect Rating Scale) ratings were evaluated in 339 in-patients with schizophrenic spectrum disorder…

AdultMalemedicine.medical_specialtyPsychosisMedizinPoison controlSuicide AttemptedComorbidityAkathisiaCohort StudiesHospitals University03 medical and health sciencesYoung Adult0302 clinical medicineRating scaleRisk FactorsGermanyHamdmedicineHumansPsychiatryPsychiatric Status Rating ScalesDepressive Disorder MajorPositive and Negative Syndrome ScaleIncidenceMiddle Agedmedicine.diseaseComorbidityHealth Surveys3. Good health030227 psychiatryPsychiatry and Mental healthCross-Sectional StudiesTreatment OutcomeSchizophreniaAcute DiseaseSchizophreniaFemaleSchizophrenic Psychologymedicine.symptomPsychology030217 neurology & neurosurgeryAkathisia Drug-InducedAntipsychotic AgentsActa psychiatrica Scandinavica
researchProduct

The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia.

2005

Positron emission tomography (PET) studies reveal that clozapine at clinically used doses occupies less than 60% of D2/D3 dopamine receptors in human striatum. Here, the occupancy of D2/D3 dopamine receptors by clozapine in patients with schizophrenia was determined to test the hypothesis that clozapine binds preferentially to extrastriatal dopamine receptors. A total of 15 clozapine-treated inpatients with schizophrenia underwent a [18F]fallypride PET scan. Receptor occupancy was calculated as percent reduction in binding potential relative to unblocked values measured in seven normal volunteers. Mean D2/D3 receptor occupancy was statistically significantly higher in cortical (inferior tem…

AdultMalemedicine.medical_specialtyPsychosisPyrrolidinesDopamineStriatumBinding CompetitiveReceptors DopamineDopamine receptor D3Internal medicinemedicineHumansClozapineClozapinePharmacologyTemporal cortexDose-Response Relationship DrugChemistryReceptors Dopamine D2PutamenReceptors Dopamine D3Middle Agedmedicine.diseaseCorpus StriatumTemporal LobePsychiatry and Mental healthEndocrinologyFallyprideDopamine receptorAnesthesiaPositron-Emission TomographyBenzamidesSchizophreniaFemalemedicine.drugAntipsychotic AgentsNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
researchProduct

Attitude towards adherence in patients with schizophrenia at discharge

2009

Abstract Background Purpose of the present study was to assess the attitude towards adherence at discharge and to verify its predictability using anamnestic and sociodemographic variables, factors influencing clinical treatment as well as the medical treatment applied. Methods Attitude towards adherence was evaluated in 369 inpatients with schizophrenic spectrum disorders within a naturalistic multicenter trial using the Compliance Rating Scale (CRS) by Kemp. Biweekly ratings of the PANSS, UKU and the Subjective Well-being under Neuroleptic Treatment Scale (SWN-K) were applied. Logistic regression and CART analyses were used to determine significant predictor variables for the attitude towa…

AdultMalemedicine.medical_specialtyPsychosisTime Factorsmedicine.drug_classmedicine.medical_treatmentAtypical antipsychoticLogistic regressionStatistics NonparametricMedication Adherence03 medical and health sciences0302 clinical medicineRating scaleSurveys and QuestionnairesMulticenter trialmedicinePsychoeducationHumansPsychiatryBiological PsychiatryRetrospective StudiesPsychiatric Status Rating ScalesMiddle Agedmedicine.diseasePatient Discharge3. Good health030227 psychiatryPsychiatry and Mental healthSchizophreniaSchizophreniaFemaleSchizophrenic PsychologyPsychologyAttitude to Health030217 neurology & neurosurgeryFollow-Up StudiesClinical psychologyPsychopathologyJournal of Psychiatric Research
researchProduct

Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open clinical trial.

2000

Antipsychotic efficacy and side effects of the selective sigma ligand EMD 57445 (panamesine) were investigated in 12 patients (6 males, 6 females) who met DSM-III-R criteria for schizophrenia. A 4-week open clinical study revealed only modest effects of EMD 57445 and its metabolites on positive and negative symptoms of schizophrenia. Extrapyramidal and other side effects were moderate, although a significant increase in mild dyskinetic movements was found. Five patients, four of whom were females, completed the trial. Dropouts were mainly due to treatment failure. Antipsychotic effects were significantly greater in female than male patients.

AdultMalemedicine.medical_specialtyPsychosismedicine.medical_treatmentSigma receptorPanamesineDrug Administration ScheduleBasal Ganglia DiseasesPiperidinesInternal medicinemental disordersmedicineHumansReceptors sigmaAntipsychoticOxazolesBiological PsychiatryBiotransformationAgedPsychiatric Status Rating ScalesDose-Response Relationship DrugMiddle Agedmedicine.diseaseClinical trialPsychiatry and Mental healthEndocrinologyTreatment OutcomeTolerabilityDopamine receptorSchizophreniaAcute DiseaseSchizophreniaFemaleSchizophrenic PsychologyPsychologyAntipsychotic AgentsPsychiatry research
researchProduct

Prevalence and correlates of QTc prolongation in Italian psychiatric care: cross-sectional multicentre study.

2016

Aims.In recent years several warnings have been issued by regulatory authorities on the risk of electrocardiogram abnormalities in individuals exposed to psychotropic drugs. As a consequence of these warnings, monitoring of the QT interval corrected for heart rate (QTc) has become increasingly common. This study was conducted to measure the frequency of QTc prolongation in unselected psychiatric patients, and to document the associated factors using a cross-sectional approach.Method.The study was carried out in 35 Italian psychiatric services that are part of the STAR (Servizi Territoriali Associati per la Ricerca) Network, a research group established to produce scientific knowledge by col…

AdultMalemedicine.medical_specialtyPsychotropic drugsEpidemiologymedicine.medical_treatmentLong QT syndromeAntidepressantDrug overdoseAdverse effectQT intervalAntipsychotic03 medical and health sciencesElectrocardiography0302 clinical medicineRisk FactorsPsychotropic drugmedicinePrevalenceHumanscardiovascular diseasesAntipsychoticAdverse effectPsychiatrySettore MED/25 - PsichiatriaPolypharmacybusiness.industryEnvironmental and Occupational HealthPublic Health Environmental and Occupational HealthAdverse effect; Antidepressant; Antipsychotic; Psychotropic drugs; Epidemiology; Public Health; Environmental and Occupational Health; Psychiatry and Mental HealthOriginal Articlesmedicine.diseaseAdverse effect; Antidepressant; Antipsychotic; Psychotropic drugs; Epidemiology; Public Health Environmental and Occupational Health; Psychiatry and Mental Health030227 psychiatrySubstance abuseLong QT SyndromeCross-Sectional StudiesItalyPsychiatry and Mental HealthPolypharmacyAripiprazoleFemalePublic HealthbusinessAntidepressant; adverse effect; antipsychotic; psychotropic drugsAdverse effect; Antidepressant; Antipsychotic; Psychotropic drugs; Adult; Antipsychotic Agents; Cross-Sectional Studies; Electrocardiography; Female; Humans; Italy; Long QT Syndrome; Male; Prevalence; Risk Factors; Polypharmacy; Epidemiology; Public Health Environmental and Occupational Health; Psychiatry and Mental Health030217 neurology & neurosurgerymedicine.drugAntipsychotic AgentsEpidemiology and psychiatric sciences
researchProduct

Prolactin plasma levels and D2-dopamine receptor occupancy measured with IBZM-SPECT

1996

By the application of 123([123I]IBZM), an iodine-labelled dopamine D2-receptor antagonist, brain D2 receptors in humans can be visualized with single photon emission computed tomography (SPECT). The ratio of IBZM binding to striatal regions versus binding to frontal cortex (ST/FC ratio) provided a semiquantitative measurement of D2 receptor binding in the striatum. This study investigated the relationship between receptor occupancy and plasma prolactin levels in 12 male patients treated with haloperidol, benperidol or clozapine. Prolactin levels were positively correlated with D2 receptor occupancy, reflecting at least in part a comparable dopamine receptor antagonism in different dopaminer…

AdultMalemedicine.medical_specialtyPyrrolidinesStriatumIodine RadioisotopesBenperidolProsencephalonDopamineDopamine receptor D2Internal medicinemedicineHumansReceptorClozapineTomography Emission-Computed Single-PhotonPharmacologySchizophrenia ParanoidReceptors Dopamine D2ChemistryBenperidolMiddle AgedCorpus StriatumProlactinProlactinEndocrinologymedicine.anatomical_structureDopamine receptorDopaminergic pathwaysBenzamidesDopamine AntagonistsHaloperidolAntipsychotic Agentsmedicine.drugPsychopharmacology
researchProduct

Occupancy of striatal D 2 -like dopamine receptors after treatment with the sigma ligand EMD 57445, a putative atypical antipsychotic

1999

Rationale: EMD 57445 (panamesine) is a high affinity sigma ligand with the profile of an atypical antipsychotic in animal studies. It has been reported recently to have antipsychotic activity in schizophrenia. However, its metabolite, EMD 59983, binds also to D2 and D3 dopamine (DA) receptors. Objectives: The aim of this study was to test, using single photon emission computed tomography (SPECT) and [123I]iodobenzamide (IBZM) as the radiotracer, whether EMD 59983 would pass the blood-brain barrier and to what extent it would contribute to the effects of EMD 57445 in schizophrenia. Methods: Two IBZM SPECT-scans were performed in five neuroleptic-free schizophrenic patients (DSM IV), one befo…

AdultMalemedicine.medical_specialtyPyrrolidinesmedicine.drug_classmedicine.medical_treatmentSigma receptorAtypical antipsychoticPanamesinePharmacologychemistry.chemical_compoundIodobenzamidePiperidinesDopamine receptor D3DopamineInternal medicinemedicineHumansReceptors sigmaAntipsychoticOxazolesTomography Emission-Computed Single-PhotonPharmacologyReceptors Dopamine D2Middle AgedCorpus StriatumPyrimidinesEndocrinologychemistryBlood-Brain BarrierDopamine receptorBenzamidesSchizophreniaFemaleAntipsychotic Agentsmedicine.drugPsychopharmacology
researchProduct

A short message service (SMS)-based strategy for enhancing adherence to antipsychotic medication in schizophrenia

2012

Abstract Background The aim of this study was to assess the impact of a short message service (SMS)-based strategy on adherence to antipsychotic treatment. Methods A multicentre, randomised, open-label, controlled, 6-month study with clinically stabilised outpatients with schizophrenia was conducted. The patients assigned to the intervention received daily SMS reminders to take their medication for 3 months. Self-reported medication adherence was determined using the Morisky Green Adherence Questionnaire (MAQ). Secondary outcomes were severity of illness, attitude towards medication, insight into illness and health-related quality of life. Results A total of 254 patients were analysed. A si…

AdultMalemedicine.medical_specialtyShort Message ServiceAdolescentmedicine.medical_treatmentMEDLINEMedication AdherenceQuality of lifeSurveys and QuestionnairesIntervention (counseling)Severity of illnessmedicineHumansPsychiatryAntipsychoticBiological PsychiatryAgedText Messagingbusiness.industryMiddle Agedmedicine.diseaseConfidence intervalPsychiatry and Mental healthTreatment OutcomeSchizophreniaSchizophreniaPhysical therapyFemalebusinessAntipsychotic AgentsPsychiatry Research
researchProduct